Design, Synthesis, and Evaluation of Homochiral Peptides Containing Arginine and Histidine as Molecular Transporters by El-Sayed, Naglaa Salem et al.
Chapman University
Chapman University Digital Commons
Pharmacy Faculty Articles and Research School of Pharmacy
6-29-2018
Design, Synthesis, and Evaluation of Homochiral
Peptides Containing Arginine and Histidine as
Molecular Transporters
Naglaa Salem El-Sayed
Chapman University
Taryn Miyake
Chapman University
Amir Nasrolahi Shirazi
Chapman University, shirazi@chapman.edu
Shang Eun Park
Chapman University
Jimmy Clark
Chapman University
See next page for additional authorsFollow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles
Part of the Amino Acids, Peptides, and Proteins Commons, Cancer Biology Commons, Medical
Biochemistry Commons, Organic Chemicals Commons, Other Chemicals and Drugs Commons,
Other Pharmacy and Pharmaceutical Sciences Commons, and the Pharmaceutical Preparations
Commons
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.
Recommended Citation
El-Sayed NS, Miyake T, Shirzai AN, et al. Design, synthesis, and evaluation of homochiral peptides containing arginine and histidine as
molecular transporters. Molecules. 2018;23(7):1590. doi: 10.3390/molecules23071590
Design, Synthesis, and Evaluation of Homochiral Peptides Containing
Arginine and Histidine as Molecular Transporters
Comments
This article was originally published in Molecules, volume 23, issue 7, in 2018. DOI: 10.3390/
molecules23071590
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright
The authors
Authors
Naglaa Salem El-Sayed, Taryn Miyake, Amir Nasrolahi Shirazi, Shang Eun Park, Jimmy Clark, Stephani
Buchholz, Keykavous Parang, and Rakesh Tiwari
This article is available at Chapman University Digital Commons: https://digitalcommons.chapman.edu/pharmacy_articles/579
molecules
Article
Design, Synthesis, and Evaluation of Homochiral
Peptides Containing Arginine and Histidine as
Molecular Transporters
Naglaa Salem El-Sayed 1,2, Taryn Miyake 1, Amir Nasrolahi Shirazi 1, Shang Eun Park 1,
Jimmy Clark 1, Stephani Buchholz 1, Keykavous Parang 1 ID and Rakesh Tiwari 1,*
1 Center for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences,
Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus,
Irvine, CA 92618, USA; nsibrahim18@gmail.com (N.S.E.-S.); miyak106@mail.chapman.edu (T.M.);
nasrolahishirazi@gmail.com (A.N.S.); park327@mail.chapman.edu (S.E.P.);
clark217@mail.chapman.edu (J.C.); buchh101@mail.chapman.edu (S.B.);
parang@chapman.edu (K.P.)
2 Cellulose and Paper Department, National Research Center, Dokki, Cairo 12622, Egypt
* Correspondence: tiwari@chapman.edu; Tel.: +1-714-516-5483
Received: 3 May 2018; Accepted: 26 June 2018; Published: 29 June 2018


Abstract: Linear (HR)n and cyclic [HR]n peptides (n = 4,5) containing alternate arginine and histidine
residues were synthesized. The peptides showed 0–15% cytotoxicity at 5–100 µM in human ovarian
adenocarcinoma (SK-OV-3) cells while they exhibited 0–12% toxicity in human leukemia cancer cell
line (CCRF-CEM). Among all peptides, cyclic [HR]4 peptide was able to improve the delivery of a
cell impermeable fluorescence-labeled phosphopeptide by two-fold. Fatty acids of different alkyl
chain length were attached at the N-terminal of the linear peptide (HR)4 to improve the molecular
transporter property. Addition of fatty acyl chains was expected to help with the permeation of
the peptides through the cell membrane. Thus, we synthesized seven fatty acyl derivatives of the
linear (HR)4 peptide. The peptides were synthesized using Fmoc/tBu solid phase peptide chemistry,
purified by reverse-phase high-performance liquid chromatography (RP-HPLC) and characterized by
matrix-assisted laser desorption/ionization (MALDI) spectrometry. The fatty acyl peptides containing
C8, C12, C14, and C18 alkyl chain did not show cytotoxicity on SK-OV-3 or CCRF-CEM cell lines up
to 50 µM concentration; however, at higher concentration (100 µM), they showed mild cytotoxicity.
For example, C16-(HR)4 was also found to reduce the proliferation of SK-OV-3 cells by 11% at 50 µM
and C20-(HR)4 showed mild toxicity at 10 µM, reducing the proliferation of SK-OV-3 cells by 21%.
Increase in the length of alkyl chain showed cytotoxicity to the cell lines. C20-(HR)4 peptide showed
better efficiency in translocation of F′-GpYEEI to SK-OV-3 than the phosphopeptide alone. Further
investigation of C20-(HR)4 peptide efficacy showed that the peptide could deliver doxorubicin and
epirubicin into SK-OV-3 and also improved the drug antiproliferative ability. These studies provided
insights into understanding the structural requirements for optimal cellular delivery of the fatty
acyl-(HR)4 peptide conjugates.
Keywords: anticancer drugs; fatty acyl peptides; histidine; phosphopeptides; molecular transporters;
cytotoxicity
1. Introduction
Cell-penetrating peptides (CPPs) also known as protein transduction domains (PTDs), are a group
of short peptides with up to 25–30 amino acids that are capable of penetrating the cell membrane.
CPPs are characterized by their high loading capacity, high transduction efficiency and rapid
Molecules 2018, 23, 1590; doi:10.3390/molecules23071590 www.mdpi.com/journal/molecules
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transduction rate [1,2]. Therefore, they are considered as good candidates for translocation of bioactive
macromolecules, such as proteins, nucleic acids, peptides, inorganic particles and liposomes into
cells [3–6].
CPPs are classified according to their physicochemical nature into amphipathic, hydrophobic or
cationic peptides. Other classification is based on the origin of CPPs, dividing them into protein-derived
CPPs, for example, TAT peptide and penetratin, model peptides as a MAP, KLAL, polyarginine,
and finally designed peptides or chimeric peptides, which consist of functional domains of target
proteins [7,8].
CPPs differ from one to another in the routes of entry and intracellular transport mechanism
for the therapeutic agents [9]. Two major routes for CPPs cellular internalization have been
proposed: direct membrane translocation via pore-opening mechanism and endocytosis-mediated
pathway, which divides into clathrin-dependent endocytosis, actin-dependent and caveolae-dependent
micropinocytosis pathways [10]. The endosomal entrapment, potential cytotoxicity, immunogenicity
and the lack of selectivity are the main obstacles that hinder the wide use of CPP’s in the fields of
imaging, drug delivery, and treatment [11].
Moreover, targeting the tumor tissue could be achieved through active targeting using specific
tumor-associated biomarkers. However, active tumor triggering approaches have some difficulties
because of the heterogeneity of the tumor tissues and the potential to develop resistance [12]. Therefore,
the development of alternate generic targeting strategies using a global feature of various cancers, such
as hypoxia [13], vasculature [14], or tumor acidic pH [15], are subjects of major interest. The diverse
properties of naturally occurring amino acids permit their use for developing multifunctional CPPs
that vary in their physicochemical properties including their degree of amphiphilicity, pKa, as well as
their biological activities.
Among these amino acids, histidine (abbreviated as His or H) is an essential amino acid with
a protonable imidazolyl group, which is required for many enzymatic activities [16]. Furthermore,
several reports emphasized the impact of incorporation of histidine amino acid into a peptide sequence
that can be used for various applications. For example, Gaspar et al. reported the successful
isolation and recovery of minicircle DNA biopharmaceuticals by using a histidine-based peptide
of sequence (C2H6)/zinc ions complex [16]. Liu et al. reported that histidine-containing nona arginine
(HR9) combined with semiconductor quantum dots (QDs) are efficient, non-toxic drug delivery
systems [17]. Li et al. demonstrated that co-grafting of arginine and histidine amino acids onto the
poly(ω-aminohexyl methacrylamide) (PAHMAA) polymer improved the polymer serum-compatibility,
gene transfection efficacy and decreased its cytotoxicity [18]. Replacement of all basic amino acids
in the antimicrobial peptide ARK24 and AKK24 by histidines yielded the histidine-rich peptides
AHH24:1 and AHH24:2, respectively and the addition of Zn2+ restored the antimicrobial activity of
the AHH peptides. Bacalum et al. reported that the substitution of tryptophan by histidine in the
antimicrobial peptide sequence R2W2RW2R2 modulated the antimicrobial activity [19].
In our previous studies, we explored the combination of attaching different hydrophobic amino
acids and charged residues with or without fatty acids to get homochiral CPPs as molecular transporters
named [WR]4 and [WR]5 [2,20–24]. Also, a further effort led to the development of new series of
peptides named [CR]4 and [CR]5 which contains cysteine and arginine residues that showed an efficient
molecular transporter’s property for a diverse group of bioactive molecules [25]. In the frame work
of developing unique CPPs to explore their application of molecular transporter properties and the
targeting of cargos to cancer cells, we aimed to develop novel CPPs with alternating arginine and
histidine amino acids to evaluate their ability to translocate various biomolecular cargoes of different
molecular size and hydrophobic nature to the cancer cells. We hypothesized that the hydrophilic
positively-charged side chain of arginine could interact with the negatively-charged phospholipid
of the cell membrane. Moreover, the hydrophilic nature and pKa value of histidine imidazolyl ring
(~6.0) could affect the transport of the cargos based on pH of cancerous cells [26]. Also, the impact of
attaching fatty acid on modulating the activity and cytotoxicity of [HR]4 peptides was investigated.
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The cytotoxicity and transporting ability for many bioactive molecules by the synthesized peptides
were studied at different peptides concentrations.
2. Result and Discussion
2.1. Chemistry
2.1.1. Synthesis of Linear and Cyclic Peptides
Four homochiral amphipathic peptides of sequence linear (HR)4, linear (HR)5, cyclic [HR]4 and
cyclic [HR]5 were synthesized by standard Fmoc solid-phase peptide synthesis (SPPS) on 2-chlorotrityl
resin as solid support. Parentheses’ ( ) represent linear (l) peptide where as square brackets’ [ ]
represent cyclic [c] peptide. All peptides were purified by preparative RP-HPLC and analyzed by
MALDI-TOF/TOF mass spectroscopy (see Supplementary Materials). Scheme 1 depicts the synthesis of
the peptides. The protected amino acids were assembled on H-Arg(Pbf)-2-chlorotrityl resin. Cleavage
of the resin in the presence of DCM:TFE:AcOH followed by cyclization generated cyclic peptides [HR]4
and [HR]5. Complete deprotection of the resin and the protecting groups in the presence of reagent R
(trifluoroacetic acid (TFA)/thioanisole/anisole/1,2-ethanedithiol (EDT) (90:5:2:3, v/v/v/v) afforded
linear peptides l(HR)4 and l(HR)5.
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2.1.2. Synthesis of Fatty Acyl Linear (HR)4 Peptides
It was expected that the attachment of fatty acids or hydrophobic residues to a cationic CPPs
will increase the peptide′s hydrophobicity. Hydrophobicity enhances the interactions with the cell
membrane phospholipids leading to increased cellular uptake, and/or modulating both activity and
selectivity [25,27–29]. Thus, a library of fatty acyl-(HR)4 peptides were synthesized using Wang resin as
the solid support as shown in Scheme 2. After peptide assembly on the solid-phase resin, the peptide
underwent reaction with a fatty acyl anhydride or other selected fatty acid namely suberic acid (C8),
lauric acid (C12), myristic acid (C14), palmitic acid (C16), oleic acid (C18), and arachidic acid (C20) using
HBTU as activating agent and DIPEA as a base. C20-(HR)2, C20-(HR)3, and C20-(HR)5, (Figure 1) were
also synthesized using a similar procedure to correlate the peptide cellular transporter activities with
the number of amino acids residues.
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2.2. Cell Assay
2.2.1. Peptide Cytotoxicity
The cytotoxicity of l(HR)4, l(HR)5, c[HR]4, and c[HR]5 was evaluated in human ovarian (SK-OV-3)
and leukemia (CCRF-CEM) cancer cells at different peptides concentrations (5, 10, 25, 50, and 100 µM)
after incubation for 24 h (Figure 2). The peptide solutions had a final concentration of 1% DMSO
in the assay. The peptides showed 5–10% toxicity at 5–100 µM peptide concentration in SK-OV-3
and 0–13% in CCRF-CEM at the same concentrations as compared to negative control (1% DMSO).
From the cytotoxicity studies, it is clear that no significant difference was observed in the peptides
cytotoxicity between linear and cyclic arginine/histidine-containing peptides and the number of amino
acids did not demonstrate a detectable difference in the toxicity profile of the four peptides at all the
investigated concentrations.
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Figure 2. Cytotoxicity study for l(HR)4, l(HR)5, c[HR]4, and c[HR]5 at 5, 10, 25, 50, and 100 µM in
SK-OV-3 and CCRF-CEM cell lines after 24 h incubation.
However, the change in the cytotoxicity profile was observed upon the attachment of fatty acids of
different chain length and degree of hydrophobicity to l(HR)4 peptide. l(HR)4 conjugated with acetyl
(C2), suberic (C8), lauroyl (C12), myristoyl (C14), and oleoyl (C18) fatty acids substituent showed 0–2%
cytotoxicity on CCRF-CEM and 0% on SK-OV-3 at 10 and 50 µM peptide concentration as compared to
negative (1% DMSO) and positive (Doxorubicin (Dox, 10 µM)) control. Increasing the concentration
to 100 µM, caused a reduction in the cell viability for l(HR)4 conjugated with C2 by 16%, C8 by 15%,
C12 by 0%, C14 by 18%, and C 8 by 27%, respectively in SK-OV-3. The viability in CCRF-CEM cell line
was reduced by 27–60% when the cells were treated ith peptides at 100 µM. Although the palmitoyl
conjugate, C16-(HR)4, had 0% cytotoxic effect on both the cell lines at 10 µM and the cell viability was
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reduced by 35–70% at peptide concentrations of 50 and 100 µM, respectively. The arachidyl peptide
conjugate, C20-(HR)4, was toxic at all concentrations, where the cell viability was significantly reduced
by (45–66%) in CCRF-CEM cells and by (31–80%) in SK-OV-3 cells, as illustrated in (Figure 3). Cancer
cells proliferate and produce lactic acid and result in acidic pH (~6.5). We assume that the observed
cytotoxicity of peptide was due to an increase of hydrophobicity of the fatty acyl peptide (C20-(HR)4)
and cellular permeability as compared to (HR)4 peptide. The pH of the media for both cancer cell
lines after 72 h of treatment for l(HR)4 peptide was found to be acidic (pH ~6.5) in comparison to
the weak basic pH (~7.5) for C20-(HR)4 treated cells. The untreated control cells were found to have
a pH of 6.5, showing 100% proliferation in the cancer cells. (HR)4 is protonated at an acidic pH of
the medium that results in membrane ionic interactions that did not improve permeability due to
the lack of hydrophobicity to interact with the lipid residues in the membrane. On the other hand,
fatty acyl compounds, such as C16-(HR)4 and C20-(HR)4 analogs, resulted in the cytotoxicity. The pH
of cellular media was found to be ~7.5 for these compounds. At this pH, the majority of histidine
residues are more deprotonated and the compound is more hydrophobic. Furthermore, C20 acyl chain
contributes to increased hydrophobicity, and more cellular permeability occurs due to the enhanced
hydrophobicity. The enhanced hydrophobicity at higher pH is due to a higher ratio of deprotonation in
histidine residues in the series of fatty acyl-(HR)4 peptides that lead to enhanced cellular permeability.
Thus, a small difference in pH (6.5–7.5) has a significant effect on the proliferation of cancer cells.
Therefore, fatty acylation significantly changed the property of l(HR)4 peptides.
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Figure 3. Cytotoxicity study for the fatty acyl-(HR)4 derivatives at concentrations of 10, 50 and 100 µM
after 72 h incubation with CCRF-CEM and SK-OV-3 cells.
2.2.2. Molecular Transporting Efficiency of the Peptides
The synthesized conjugated peptides were evaluated for their ability to mediate the cellular
internalization for fluorescence-labeled phosphopeptide containing the sequence F′-GpYEEI (where F′
represents carboxyfluorescein and pY represents phosphotyrosine amino acid). Phosphopeptides are
considered as reagent probes that mimic phosphoproteins involved in signal transduction. They are
usually employed in studying the mechanism of phosphoprotein–protein, protein-ligand interactions,
the determination of phosphatases enzyme’s specificity to substrates, and the identification of
phosphotyrosine receptors binding domains (PTB) [21,30]. The presence of negatively-charged
phosphate groups in addition to the hydrophobic nature of phosphopeptides limited their ability
to bypass the cell membrane and reduce their cellular uptake. Consequently, several approaches
have been suggested to promote their transportation through the cell membrane into the cell
cytoplasm [21,26].
Fluorescently labeled phosphopeptide F′-GpYEEI at a concentration of 5 µM was incubated with
the linear and cyclic peptides (l(HR)4, l(HR)5, c[HR]4, and c[HR]5) at a concentration of 50 µM for 2 h.
The cellular internalization for F′-GpYEEI by c[HR]5, l(HR)4, and l(HR)5 did not differ significantly
Molecules 2018, 23, 1590 7 of 15
from that of the phosphopeptide alone. However, the cellular uptake of F′-GpYEEI was increased by
two folds when loaded with c[HR]4. These data indicate that only cyclic [HR]4 was able to promote
the delivery of F′-GpYEEI (Figure 4).
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Figure 4. Cellular uptake study of F′-GpYEEI phosphopeptide at 5 µM by c[HR]4, c[HR]5, l(HR)4,
and l(HR)5 at 50 µM peptide concentration in SK-OV-3 cancer cell lines.
The four alternate H and R residues showed ability in delivering phosphopeptide (F′-GpY EI)
inside the SK-OV-3 ce ls. Therefore, we investigated the impact of a tachment of fa ty acyl chain with
di ferent hydrophobic alkyl chains to l(HR)4 in modulating the cellular uptake using fa ty acylation
strategy [ ]. The conjugation of fatty cyl chain to l(HR)4 peptide affected the molecular transportation
ability of F′-GpYEEI peptide. When F′-GpYEEI was incubated with the fatty acyl-(HR)4 peptides at a
concentration of 50 µM for 2 h, it was found that C16-(HR)4 and C20-(HR)4 were the most effective in
promoting the cellular uptake. They improved the cellular uptake of F′-GpYEEI by 1.5 and 2.0 folds,
respectively, as com ared to the free form of F′-GpYEEI. Fatty acyl (HR)4 peptides ontaining acetyl or
suberoyl moi ties increased the uptake of F′-GpYEEI by 10%, while (HR)4 peptides with the lauroyl,
myristoyl, and oleoyl moieties slightly reduced the uptake of F′-GpYEEI (Figure 5). Furthermore,
the c llular ptake f F′-GpYEEI mediated by C20-(HR)4 proved to be a concentrati n-dependent.
For example, C20-(HR)4 incr ased the uptake of F′-GpYEEI by bout a factor of two at 5 µM and
increased by a factor of 2.5 at concen ration 10 µM as shown i (Figure 6).
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SK-OV-3 cancer cell lines.
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Figure 6. Cellular uptake studies F′-GpY EI (5 µM) in the pr sence of C20-(HR)4 in SK-OV-3 cell lines
at a concentration of 5, 10 and 50 µM of C20-(HR)4.
Then we compared the cellular uptake of F′-GpYEEI with C20-(HR)4, l(HR)4, and c[HR]4 at
50 µM in the SK-OV-3 cells. Figure 7 showed that the C20-(HR)4 was found to be the most effective in
mediating the cellular uptake of F′-GpYEEI after 4 h by more than five folds as compared to ~2 folds
by the c[HR]4 in the SK-OV-3 cells.
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Figure 7. Comparative study for the cellular uptake of F′-GpYEEI (5 µM) by l(HR)4, c[HR]4,
and C20-(HR)4 at 50 µM in SK-OV-3 cell line.
itiona ly, t tr fi f 2
e ti es as t ie si - ll li . Increasing the nu ber of isti ine a r i i e
a ino acids (n = 2–5), increased the potent ality of C20-(HR)n peptides in translocating F′-GpYEEI
into the C RF-CEM cells after 3 . The C20-(HR)2 p pti e did not mediate the cellular uptake of
F′-GpYEEI. C20-(HR)5 peptide increased the cell lar uptake by more than 10 times. Meanwhile, both
C20-(HR)4 and C20-(HR)3 pept des displayed the same ability in translocating F′-GpYEEI into the
CRF-CEM cells. Both C20-(HR)4 and C20-(HR)3 f tt acyl peptides incr ased the cellular uptake f
. 4.5 ti es respectively as compared to the free F′-GpYEEI (Figure 8).
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Figure 8. The cellular uptake of F′-GpYEEI at 5 µM concentration by C20-(HR)n peptides at 50 µM
peptide concentration in CCRF-CEM cell line.
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2.2.3. Anticancer Drug Delivery Using C20-(HR)4
The efficiency of C20-(HR)4 as drug carrier was evaluated by incubating the peptide at 50 µM
concentration with different anticancer drugs including (doxorubicin, etoposide, cisplatin, epirubicin,
paclitaxel, and gemcitabine) at a drug concentration of 5 µM for 72 h, as shown in the (Figure 9).
The anti-proliferation potency of doxorubicin and epirubicin significantly improved by two fold
upon their loading with C20-(HR)4. The physical mixture of paclitaxel or gemcitabine with C20-(HR)4
peptide increased the drug toxicity only by 1.5 fold. On the other hand, C20-(HR)4 did not improve the
anti-proliferating potency of etoposide and paclitaxel in CCRF-CEM cell line but the cell viability in
SK-OV-3 cell line was reduced by almost one and half fold as compared to the parent analogs.
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Figure 9. Anti-proliferativ assay re ults for C20-(HR)4 with different anticancer drugs.
3. Materi ls and Methods
3.1. General Information
All amino acids were pu chased from Chem-Impex Interna io l, I c. All other c micals and
reagents were purchased from Sig a-Aldrich Chemical Co. (Milwaukee, WI, USA). The chemical
structu es of final products were confirmed by high-resolution MALDI ABX SCIEX TOF/ 5800 at
the University of California, Irvine, mass spectroscopy facility. The reactions for peptide synthesis were
carried out in Bio-Rad polypropylene columns by shaking and mixing under nitrogen using a Glass-Col
small tube r tator at room temperature according to our previously re orted proc du e [20–23].
The peptides were synthesized by solid-phase synthesis using N-(9-fluorenyl)-methoxycarbonyl
(Fmoc)-based hemistry and employing F oc-L-amino acid building blocks. L ear peptides, (HR)4,
(HR)5 and cyclic peptides [ ]4 and [HR]5, were synthesized by solid-phase synthesis using
NH2-Arg(Pbf)-2-chlorotrityl resin. 2-(1H−Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium h xafluoro
phosphate (HBTU) a d N,N-diisop pylethyl mine (DIPEA) in ,N-dimethylformamide (DMF) were
used as coupling and activating reag nts, respectively. Fmoc deprotection at each step wa carried out
using pi eridine in DMF (20% v/v). For the peptide synthesis, as representative examples, the synthesis
of linear (HR)4, cyclic [HR]4 and fatty acyl lauryl-(HR)4 derivatives are des r bed below.
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3.1.1. Synthesis of Linear (HR)4
The linear peptide containing eight amino acids of alternative histidine and arginine residues
(HRHRHRHR) was synthesized by Fmoc/tBu solid-phase peptide synthesis. H-Arg(Pbf)-2-chlorotrityl
resin (0.3 mmol, 732 mg, 0.41 mmol/g) was swelled in DMF and Fmoc groups were deprotected
using 20% piperidine/DMF under nitrogen for two times (20 min × 2). Fmoc-His(Trt)-OH
(557.74 mg, 0.9 mmol) and Fmoc-Arg(Pbf)-OH (583.89 mg, 0.9 mmol) were coupled alternatively
to NH2-Arg(Pbf)-2-chlorotrityl resin in the presence of HBTU (341.32. mg, 0.9 mmol) and DIPEA
(315 µL, 1.8 mmol) in DMF. Coupling and deprotection cycles were repeated to assemble the sequence
of the linear protected peptide. Then, the side-chain deprotection and cleavage from the resin were
carried out by a cleavage cocktail reagent “R” (TFA/thioanisole/anisole/1,2-ethanedithiol (EDT),
90:5:2:3, v:v:v:v, 15 mL) for 5 h. The crude peptide was precipitated by the addition of cold diethyl
ether (75 mL, Et2O) and purified by reversed-phase Hitachi HPLC (L-2455) on a water X Bridge TM
BEH130 Prep C18 OBD 10 µm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system.
The crude peptide was purified at a flow rate of 10.0 mL/min using a gradient of 0–100% acetonitrile
(0.1% TFA) and water (0.1%TFA) over 60 min on RP-HPLC and then was lyophilized to obtain the
linear peptide. l(HR)4: MALDI-TOF (m/z): C48H78N28O9, calcd. 1190.6507; found 1191.5143 [M]+.
Similarly, l(HR)5 was synthesized. l(HR)5: MALDI-TOF (m/z): C60H97N35O11; calcd. 1483.8107; found
1484.7310 [M + H]+.
3.1.2. Synthesis of Cyclic [HR]4 Peptide
The linear peptide was assembled on H-Arg(Pbf)-2-chlorotrityl resin (0.3 mmol, 732 mg,
0.41 mol/g) after swelling in DMF for 30 min under nitrogen. Fmoc-His(Boc)-OH (473.9 mg, 0.9 mmol)
and Fmoc-Arg(Pbf)-OH (583.9 mg, 0.9 mmol) were coupled alternatively as described above to
synthesize linear peptide assembled on the resin. The side chain protected peptide was cleaved from the
resin by shaking the resin with a mixture of trifluoroethanol (TFE)/acetic acid/dichloromethane (DCM)
(2:2:6, v/v/v, 50 mL) for 2 h. The resin was filtered off and the solution was evaporated to dryness under
reduced pressure to yield side-chain protected linear peptide. Then cyclization of the linear peptide was
carried out in the presence of DIC (140 µL, 0.9 mmol) and HOAt (122.5 mg, 0.9 mmol) in dry DMF/DCM
(200 mL, 3:1 v/v) under nitrogen stirring for 12 h. After cyclization, the solvent was evaporated and
the side chain deprotection was performed by addition of TFA/thioanisole/anisole/EDT (90:5:2:3,
v:v:v:v, 15 mL) and shaking on a shaker for 5 h. The crude peptide was precipitated by the addition of
cold diethyl ether (75 mL, Et2O) and purified by reversed-phase Hitachi HPLC (L-2455) on a Waters
XBridgeTM BEH130 Prep C18 OBDTM 10 µm ODS reversed-phase column (2.1 cm × 25 cm) using
a gradient system. The crude peptide was purified at a flow rate of 10.0 mL/min using a gradient
of 0–100% acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min and then was lyophilized to
yield the pure cyclic peptide c[HR]4: MALDI-TOF (m/z) for C48H76N28O8, calcd. 1172.6401; found
1173.6167, [M + H]+. Similarly, c[HR]5 was synthesized. c[HR]5: MALDI-TOF (m/z): C60H95N35O10;
calcd. 1465.8001; found 1466.8918 [M + H]+.
3.1.3. Synthesis of Lauryl-(HR)4 Peptide
The synthesis of fatty acyl derivatives of linear (HR)4 peptides were carried on solid-phase.
The peptide was synthesized using Fmoc-Arg(Pbf)-Wang resin (0.3 mmol, 750.0 mg, 0.40 mmol/g).
Once, the linear peptide was assembled after coupling Fmoc-His(Trt)-OH (557.74 mg, 0.9 mmol) and
Fmoc-Arg(Pbf)-OH (583.90 mg, 0.9 mmol) alternatively using HBTU (341.32. mg, 0.9 mmol) and
DIPEA (315 µL, 1.8 mmol) in DMF for 1 h with Fmoc deprotection in between each coupling cycle
using 20% piperidine in DMF. After the last coupling was completed, the resin was washed with DMF
(3× 15 mL) followed by N-terminal Fmoc deprotection using 20% piperidine in DMF (2 × 10 mL,
10 min each). Then, lauric acid (180 mg, 0.9 mmol) was coupled to the N-terminal of the linear (HR)4
peptide using HBTU (341.32. mg, 0.9 mmol) and DIPEA (315 µL, 1.8 mmol) in the DMF. The resin
Molecules 2018, 23, 1590 12 of 15
was washed with DCM (3 × 25 mL) and methanol (3 × 25 mL) and vacuum dried. Then the resin
and the side chain protecting groups were cleaved from the peptidyl resin using cleavage cocktail
TFA/thioanisole/EDT/anisole (90:5:3:2, v:v:v:v, 15 mL) for 5 h. The crude peptide was precipitated
by adding cold diethyl ether (100 mL, Et2O) and centrifuged at 4000 rpm for 10 min, followed by
decantation to obtain the solid precipitate. The solid material was further washed with cold ether
(2 ×100 mL) for 2 times. The peptide was resolubilized in a solvent (CH3CN + 0.1% TFA and water
+ 0.1% TFA). The crude peptide was purified by using the reverse-phase high performance liquid
chromatography (RP-HPLC) equipped with a Waters XBridgeTM BEH130 Prep C18 column OBDTM
10 µm (19 mm × 250 mm). A gradient of 0–100% acetonitrile and water in 0.1% TFA (v/v) with
a flow rate at 10.0 mL/min was used for the purification. The peptide powder was obtained after
lyophilization of pure HPLC fraction. Other fatty acid conjugates of (HR)4 were synthesized in a
similar manner:
CH3CO-(HR)4: MALDI-TOF (m/z): C50H80N28O10; calcd, 1232.6612; found 1233.5829 [M + H]+;
COOH-(CH2)6-CO-(HR)4: MALDI-TOF (m/z): C56H90N28O12; calcd, 1346.7293; found 1347.5835
[M + H]+; CH3-(CH2)10-CO-(HR)4: MALDI-TOF (m/z): C60H100N28O10; calcd, 1372.8177; found
1373.8236 [M + H]+; CH3-(CH2)12-CO-(HR)4: MALDI-TOF (m/z): C62H104N28O10; calcd, 1400.8490
found 1401.6533 [M + H]+; CH3-(CH2)14-CO-(HR)4: MALDI-TOF (m/z): C64H108N28O10; calcd,
1428.8803; found 1429.9110 [M + H]+; CH3-(CH2)7CH=CH(CH2)7-CO-(HR)4: MALDI-TOF
(m/z): C66H109N28O10; calcd, 1454.8960; found 1455.6722 [M + H]+; CH3-(CH2)18-CO-(HR)4:
MALDI-TOF (m/z): C68H111N28O10; calcd, 1484.9429; found 1485.7854 [M + H]+;
CH3-(CH2)18-CO-(HR)5: MALDI-TOF (m/z): C80H135N35O12; calcd, 1778.1029; found 1778.8019
[M]+; CH3-(CH2)18-CO-(HR)3: MALDI-TOF (m/z): C56H79N21O8; calcd, 1191.7829; found, 1192.7028
[M + H]+; CH3-(CH2)18-CO-(HR)2: MALDI-TOF (m/z): C62H104N28O10; calcd, 898.6229 found,
899.3463; [M + H]+.
3.2. Cell Culture
Human leukemia CCRF-CEM (ATCC no. CCL-119) and ovarian carcinoma SK-OV-3 (ATCC no.
HTB-77) cell lines were obtained from American Type Culture Collection. Cells were grown on 75 cm2
cell culture flasks with Roswell Park Memorial Institute (RPMI)-1640 medium (for CCRF-CEM) and
Eagle’s minimum essential medium (EMEM) (for SK-OV-3), supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin−streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in
0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 ◦C. All bioassays were performed
in triplicate.
3.3. Cell Viability Assays Using MTT
The cytotoxicity assay was performed via an MTS proliferation assay in CCRF-CEM and SK-OV-3
cells. 5000 cells were incubated with 100 µL of complete media and allowed to grow for overnight
in each well of the 96 well plates. The linear and cyclic peptides at concentrations (5, 10, 25, 50 and
100 µM) were added to the cells and incubated at 37 ◦C with 5% carbon dioxide for 72 h. After 72 h of
incubation, the pH of media were tested. Both cell lines with/without (HR)4 treatment were found to
be acidic (~6.5) whereas the cells treated with C20-(HR)4 were slightly basic (pH ~7.5). Then 20 µL of
MTS reagent was added to each well. CCRF-CEM cells were incubated for 3 h, and SK-OV-3 cells were
incubated for 1 h at 37 ◦C with 5% carbon dioxide. The fluorescence intensity of the formazan product
was measured at 490 nm using a Spectra Max M2 microplate spectrophotometer. The percentage of
cell survival was calculated as [(OD value of cells treated with the test mixture of compounds) −
(OD value of culture medium)]/[(OD value of control cells) − (OD value of culture medium)] × 100%.
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3.4. Cellular Uptake Studies of Fluorescein-Labeled Phosphopeptide by Flow Cytometry
The cellular uptake assays were performed via FACS analysis using SK-OV-3 and CCRF-CEM cells
in 6-well plates. The fluorescein-labeled phosphopeptide (F′-GpYEEI) was added to the well plates
at a concentration of 5 µM, and the peptides were added to the well in each plate at a concentration
of 5, 10 and 50 µM. The cells were incubated at 37 ◦C with 5% carbon dioxide for 2 h. The cells were
digested with 0.25% trypsin, 0.53 mM EDTA for 5 min to detach from the surface followed by addition
of 2 mL of complete media to deactivate the trypsin. The cells were centrifuged at 2500 rpm and
washed with PBS for two times. Finally, the cells were resuspended in 400 µL of flow cytometry buffer
and analyzed by flow cytometry. The data presented are based on the mean fluorescence signal for
10,000 cells collected. All assays were performed in triplicate.
3.5. Antiproliferative Assay of the Anticancer Drugs Using C20-(HR)4
The antiproliferative assay was performed using MTT proliferation assay in CCRF-CEM and
SK-OV-3 cells. The cells were incubated with 100 µL of complete media overnight in a 96 well
plate. The anticancer drugs namely (Doxorubicin, Etoposide, Cis-platin, Epirubicin, Paclitaxel,
and Gemcitabine) were added to the well plates at a concentration of 5 µM and C20-(HR)4 was
added to the cells at a concentration of 50 µM. The cells were incubated at 37 ◦C with 5% CO2 for 72 h.
Then 20 µL of MTT was added to each well. After addition of MTT reagent, CCRF-CEM cells were
incubated for 3 h and SK-OV-3 cells were incubated for 1 h at 37 ◦C with 5% CO2. The absorbance
(and thus percent cell viability) was obtained at a wavelength of 490 nm using a microplate reader.
4. Conclusions
In conclusion, a new series of linear and cyclic homochiral amphipathic peptides, which consists
of alternating arginine and histidine amino acids, were synthesized. Both linear and cyclic peptides
showed 0–13% cytotoxicity on SK-OV-3 and CCRF-CEM. Among the investigated peptides, c[HR]4
proved to be promising as molecular transporters for F′-GpYEEI phosphopeptide. The attachment of
different fatty acids to l(HR)4 peptide modulated its toxicity profile and molecular transporter property.
C2-, C8-, C12-, C14-, C18-(HR)4 were not toxic up to 50 µM concentration while C16-(HR)4 and C20-(HR)4
exhibited a significant reduction in the cell viability at the same concentration. Our studies revealed
that the cellular uptake of F′-GpYEEI phosphopeptide by C20-(HR)4 was significantly improved and
was concentration dependent. Increasing the number of amino acids increased the efficacy of the
C20-[HR]n peptide in translocating F′-GpYEEI phosphopeptide into the cells. When C20-(HR)4 mixed
with several anticancer drugs, the antiproliferation potency of doxorubicin and epirubicin increased
more than the parent alone in SK-OV-3 cell line.
Supplementary Materials: The supplementary materials are available online containing MALDI-MS spectra of
synthesized peptides.
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